Research

The University of Pittsburgh Department of Medicine is a formidable leader in cutting-edge research. Our basic scientists, clinical researchers, and clinicians work daily to make research discoveries that will positively impact the world’s healthcare.

Our numbers:

  • With 665 faculty, we are the largest department within the University of Pittsburgh School of Medicine.
  • Our NIH funding level is ranked in the top 10 nationally among other Departments of Internal Medicine.
  • The medical school’s NIH funding level ranks fifth in the nation.

Our scientists, physician-scientists, and clinicians do the advanced research that is changing people’s lives—and furthering our understanding of science. The papers they publish in high-impact journals … the grants and training awards they receive, including five new T32s in fiscal year 2015-16 … are all reflections of our investigators’ skill, dedication, and commitment.

Latest High-Impact Publications
JCI InsightUnexpected kidney-restricted role for IL-17 receptor signaling in defense against systemic Candida albicans infection.
Ramani K, Jawale CV, Verma AH, Coleman BM, Kolls JK, Biswas PS.
JCI Insight.2018 May 3;3(9). pii: 98241. doi: 10.1172/jci.insight.98241.
Nature ImmunologyIL-17 metabolically reprograms activated fibroblastic reticular cells for proliferation and survival.
Majumder S, Amatya N, Revu S, Jawale CV, Wu D, Rittenhouse N, Menk A, Kupul S, Du F, Raphael I, Bhattacharjee A, Siebenlist U, Hand TW, Delgoffe GM, Poholek AC, Gaffen SL, Biswas PS, McGeachy MJ.
Nat Immunol. 2019 May;20(5):534-545. doi: 10.1038/s41590-019-0367-4. Epub 2019 Apr 8.
PNASConcentric organization of A- and B-type lamins predicts their distinct roles in the spatial organization and stability of the nuclear lamina.
Nmezi B, Xu J, Fu R, Armiger TJ, Rodriguez-Bey G, Powell JS, Ma H, Sullivan M, Tu Y, Chen NY, Young SG, Stolz DB, Dahl KN, Liu Y, Padiath QS.
Proc Natl Acad Sci U S A. 2019 Feb 14. pii: 201810070. doi: 10.1073/pnas.1810070116. [Epub ahead of print]
Cell MetabInhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by _-Catenin Mutations.
Adebayo Michael AO, Ko S, Tao J, Moghe A, Yang H, Xu M, Russell JO, Pradhan-Sundd T, Liu S, Singh S, Poddar M, Monga JS, Liu P, Oertel M, Ranganathan S, Singhi A, Rebouissou S, Zucman-Rossi J, Ribback S, Calvisi D, Qvartskhava N, Gšrg B, HŠussinger D, Chen X, Monga SP.
Cell Metab. 2019 Jan 28. pii: S1550-4131(19)30002-6. doi: 10.1016/j.cmet.2019.01.002. [Epub ahead of print]
NEJMAntibody-Mediated Rejection of Solid-Organ Allografts.
Lakkis FG, Chalasani G, Hariharan S.
N Eng J Med. 2018 Dec 27;379(26):2580. doi: 10.1056/NEJMc1813976.
JAMASerum Creatinine in the Critically Ill Patient With Sepsis.
Legrand M, Kellum JA.
JAMA. 2018 Dec 11;320(22):2369-2370. doi: 10.1001/jama.2018.16627.
J Clin InvestKidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted.
Tilstra JS, Avery L, Menk AV, Gordon RA, Smita S, Kane LP, Chikina M, Delgoffe GM, Shlomchik MJ.
J Clin Invest. 2018 Nov 1;128(11):4884-4897. doi: 10.1172/JCI120859. Epub 2018 Sep 24.
NEJMA Randomized Trial of a Family-Support Intervention in Intensive Care Units.
White DB, Angus DC, Shields AM, Buddadhumaruk P, Pidro C, Paner C, Chaitin E, Chang CH, Pike F, Weissfeld L, Kahn JM, Darby JM, Kowinsky A, Martin S, Arnold RM; PARTNER Investigators.
N Eng J Med. 2018 Jun 21;378(25):2365-2375. doi: 10.1056/NEJMoa1802637
NEJMMimicking Factor VIII to Manage the Factor VIII-Deficient State.
Ragni MV.
N Eng J Med. 2018 Aug 30;379(9):880-882. doi: 10.1056/NEJMe1808789
Latest Grants, $ 1 Million and Above
liebschutzPI: Jane Liebschutz, MD, MPH, Division of General Internal Medicine
Agency: NIDA
Title: Appalachian Node
Project timeline: 06/15/2019 - 02/29/2024
Direct Costs: $4,356,058
Indirect Costs: $1,410,035
Type of Grant: UG1
magnaniPI: Jared Magnani, MD, MSc, Division of Cardiology
Agency: NHLBI
Title: Mobile Health Intervention for Rural Atrial Fibrillation
Project timeline: 08/01/2019 - 07/31/2023
Direct Costs: $2,182,465
Indirect Costs: $830,674
Type of Grant: R01
tudorascuPI: Dana Tudorascu, PhD, Division of General Internal Medicine
Agency: NIA
Title: Statistical Methods to Improve Reproducibility and Reduce Technical Variability in Heterogeneous Multimodal Neuroimaging Studies of AlzheimerÕs Disease
Project timeline: 08/15/2019 - 04/30/2024
Direct Costs: $2,136,335
Indirect Costs: $879,165
Type of Grant: R01
subramanyaPI: Arohan Subramanya, MD, Renal-Electrolyte Division
Agency: NIDDK
Title: Regulation of Renal WNK Signaling in Intercalated Cells
Project timeline: 07/23/2019 - 06/30/2024
Direct Costs: $1,745,180
Indirect Costs: $746,269
Type of Grant: R01
rubioPI: Doris Rubio, PhD, Division of General Internal Medicine
Agency: NIGMS
Title: Building Up
Project timeline: 08/15/2019- 06/30/2024
Direct Costs: $1,693,625
Indirect Costs: $852,132
Type of Grant: U01
biswasPI: Partha Biswas, BVSc, MVSc, PhD, Division of Rheumatology and Clinical Immunology
Agency: NIAID
Title: Mechanisms of neutrophil dysfunction in antifungal immunity
Project timeline: 08/07/2019 - 07/31/2024
Direct Costs: $1,549,308
Indirect Costs: $855,011
Type of Grant: R01
formanPI: Daniel Forman, MD, Division of Geriatric Medicine
Agency: NIA
Title: Nitrite Therapy to Improve Mitochondrial Energetics and Physical Activity in Older Adults
Project timeline: 03/01/2019 - 11/30/2022
Direct Costs: $1,508,574
Indirect Costs: $439,357
Type of Grant: R01
stockerPI: Sean Stocker, PhD, Renal-Electrolyte Division
Agency: NHLBI
Title: Brain NaCl-sensing in salt-sensitive hypertensionBrain NaCl-sensing in salt-sensitive hypertension
Project timeline: 07/10/2019 - 04/30/2023
Direct Costs: $1,440,056
Indirect Costs: $797,812
Type of Grant: R01
alghoulehPI: Imad Al Ghouleh, PhD, Division of Cardiology
Agency: NHLBI
Title: Endothelial Reprogramming in Pulmonary Hypertension
Project timeline: 07/01/2019 - 06/30/2024
Direct Costs: $1,250,000
Indirect Costs: $697,775
Type of Grant: R01
janet leePI: Janet S. Lee, MD, Division of Pulmonary, Allergy and Critical Care Medicine
Agency: Ohio State University/NIH
Title: Immunosuppression in Acute Lung Injury - Proj 4
Project timeline: 05/01/2019 - 04/30/2024
Direct Costs: $1,206,455
Indirect Costs: $659,040
Type of Grant: P01
chunbin zouPI: Chunbin Zou, MD, PhD, Division of Pulmonary, Allergy and Critical Care Medicine
Agency: NHLBI
Title:Epigenetic Modulation in Septic Immunosuppression
Project timeline: 05/15/2019 - 03/21/2023
Direct Costs: $1,181,032
Indirect Costs: $667,283
Type of Grant: R01
gladwinPI: Mark Gladwin, MD, Vascular Medicine Institute
Agency: NHLBI
Title: 1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
Project timeline: 05/15/2019 - 04/30/2020
Direct Costs: $1,011,620
Indirect Costs: $381,930
Type of Grant: UG3